Identification:
unj_so19_02
Issue:
September-October 2019
Volume:
Volume 39 Number 5
Credits(Post Test and/or Evaluation Required) Available until 10/31/2021
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure: The author(s), editor, editorial board, content reviewers, and education director reported no actual or potential conflict of interest in relation to this continuing nursing education article. Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: This educational activity is provided by the Society of Urologic Nurses and Associates (SUNA).
The Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556.
This article was reviewed and formatted for contact hour credit by Michele Boyd, MSN, RN-BC, SUNA Education Director. Learning Outcome: After completing this educational activity, the learner will be able to discuss the evolution of prostate cancer treatment and how these advances optimize overall survival rates. Learner Engagement Activity: For more information about prostate cancer, consult the following website: American Cancer Society (2019). Key statistics for prostate cancer. Retrieved from https://www.cancer.org/cancer/...